Literature DB >> 15485024

Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"?

T L Th A Jansen, M K Reinders, E N van Roon, J R B J Brouwers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15485024

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  15 in total

1.  Rasburicase treatment in severe tophaceous gout: a novel therapeutic option.

Authors:  J D Moolenburgh; M K Reinders; T L Th A Jansen
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

2.  Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.

Authors:  Mattheus K Reinders; Eric N van Roon; Pieternella M Houtman; Jacobus R B J Brouwers; Tim L Th A Jansen
Journal:  Clin Rheumatol       Date:  2007-02-17       Impact factor: 2.980

Review 3.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

Review 4.  Management of hyperuricemia in gout: focus on febuxostat.

Authors:  Mattheus K Reinders; Tim L Th A Jansen
Journal:  Clin Interv Aging       Date:  2010-02-02       Impact factor: 4.458

5.  New advances in the treatment of gout: review of pegloticase.

Authors:  Mattheus K Reinders; Tim L Th A Jansen
Journal:  Ther Clin Risk Manag       Date:  2010-10-27       Impact factor: 2.423

Review 6.  Gout: optimizing treatment to achieve a disease cure.

Authors:  José Antonio Bernal; Neus Quilis; Mariano Andrés; Francisca Sivera; Eliseo Pascual
Journal:  Ther Adv Chronic Dis       Date:  2016-01-12       Impact factor: 5.091

Review 7.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Authors:  Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 9.  A historical journey of searching for uricosuric drugs.

Authors:  Tim LThA Jansen; Giesen Tanja; Janssen Matthijs
Journal:  Clin Rheumatol       Date:  2021-09-28       Impact factor: 2.980

10.  Structure-activity relationships of benzbromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agents.

Authors:  Ram Naresh Pandey; Tim Sen Wang; Emmanuel Tadjuidje; Matthew G McDonald; Allan E Rettie; Rashmi S Hegde
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.